Document:

Exhibit 4.5

 

FIRST AMENDMENT

TO THE

VERIFYME,
INC.

2020 EQUITY INCENTIVE PLAN

 

The VerifyMe, Inc. 2020 Equity
Incentive Plan (the “Plan”) is hereby amended as follows, effective June 9, 2022:

 

1.       Section
5.1(a) of the Plan is hereby amended and restated in its entirety to provide as follows:

 

“(a)       Available
Shares. Subject to adjustment as provided in Section 12, the maximum number of shares of Common Stock reserved and available for grant
and issuance pursuant to the Plan as of the Effective Date will be (i) 2,069,110, plus (ii) the number of shares of Common Stock available
for issuance under the Prior Plan on the Effective Date. If the Plan is approved by the stockholders of the Company on the Effective Date,
no awards may be granted under the Prior Plan on or after the Effective Date.”

 

*      *      *      *      *Exhibit
4.1

 

DESCRIPTION
OF CAPITAL STOCK

 

We
have authorized capital stock consisting of 50,000,000 shares of common stock, $0.001 par value per share.

 

As
of the date of this annual report on Form 10-K, we had 26,693,004 shares of our common stock outstanding.

 

The
following description of our capital stock is a summary only and is subject to and qualified in its entirety by reference to the applicable
provisions of the Nevada Revised Statutes, and our charter and Bylaws. You should refer to, and read this summary together with, our
Articles of Incorporation and Bylaws, each as amended and restated to date, to review all of the terms of our capital stock. Our Articles
of Incorporation and amendments thereto are incorporated by reference as exhibits to our annual report.

 

Common
Stock

 

Each
share of our common stock is entitled to equal dividends and distributions per share with respect to the common stock when, as and if
declared by our Board of Directors. No holder of any shares of our common stock has a preemptive right to subscribe for any of our securities,
nor are any shares of our common stock subject to redemption or convertible into other securities. Upon liquidation, dissolution or winding-up
of the Company, and after payment to our creditors and preferred stockholders, if any, our assets will be divided pro rata on a share-for-share
basis among the holders of our common stock. Each share of our common stock is entitled to one vote on all stockholder matters. Shares
of our common stock do not possess any cumulative voting rights.

 

The
presence of the persons entitled to vote a majority of the outstanding voting shares on a matter before the stockholders constitute the
quorum necessary for the consideration of the matter at a stockholders’ meeting.

 

Except
as otherwise required by law, the Articles of Incorporation, or any certificate of designations, (i) at all meetings of stockholders
for the election of directors, a plurality of votes cast are sufficient to elect such directors; (ii) any other action taken by stockholders
are be valid and binding upon the Company if the number of votes cast in favor of the action exceeds the number of votes cast in opposition
to the action, at a meeting at which a quorum is present, except that adoption, amendment or repeal of the Bylaws by stockholders requires
the vote of a majority of the shares entitled to vote; and (iii) broker non-votes and abstentions are considered for purposes of establishing
a quorum but not considered as votes cast for or against a proposal or director nominee. Each stockholder has one vote for every share
of stock having voting rights registered in his or her name, except as otherwise provided in any preferred stock designation setting
forth the right of preferred stock stockholders.

 

The
common stock does not have cumulative voting rights, which means that the holders of 51% of the common stock voting for election of directors
can elect 100% of our directors if they choose to do so.

 

Anti-Takeover
Provisions Under The Nevada Revised Statutes

 

Certain
provisions of Nevada law, and our Articles of Incorporation and our Bylaws (subject, where applicable as described below, our opting
out of certain provisions of Nevada law), contain provisions that could make the following transactions more difficult: acquisition of
us by means of a tender offer; acquisition of us by means of a proxy contest or otherwise; or removal of our incumbent officers and directors.
It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise
consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market
price for our shares.

 

These
provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are
also designed to encourage persons seeking to acquire control of us to first negotiate with our Board of Directors. We believe that the
benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to
acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result
in an improvement of their terms. 

 

    	 

     

    

 

Business
Combinations

 

Sections
78.411 to 78.444 of the Nevada revised statues (the “NRS”) prohibit a Nevada corporation from engaging in a “combination”
with an “interested stockholder” for three years following the date that such person becomes an interested stockholder
and place certain restrictions on such combinations even after the expiration of the three-year period. With certain exceptions, an interested
stockholder is a person or group that owns 10% or more of the corporation’s outstanding voting power (including stock with respect
to which the person has voting rights and any rights to acquire stock pursuant to an option, warrant, agreement, arrangement, or understanding
or upon the exercise of conversion or exchange rights) or is an affiliate or associate of the corporation and was the owner of 10% or
more of such voting stock at any time within the previous three years.

 

A
Nevada corporation may elect not to be governed by Sections 78.411 to 78.444 by a provision in its Articles of Incorporation. We do not
have such a provision in our Articles of Incorporation, as amended, pursuant to which we have elected to opt out of Sections 78.411 to
78.444; therefore, these sections apply to us.

 

Control
Shares

 

Nevada
law also seeks to impede “unfriendly” corporate takeovers by providing in Sections 78.378 to 78.3793 of the NRS that
an “acquiring person” shall only obtain voting rights in the “control shares” purchased by such
person to the extent approved by the other stockholders at a meeting. With certain exceptions, an acquiring person is one who acquires
or offers to acquire a “controlling interest” in the corporation, defined as one-fifth or more of the voting power.
Control shares include not only shares acquired or offered to be acquired in connection with the acquisition of a controlling interest,
but also all shares acquired by the acquiring person within the preceding 90 days. The statute covers not only the acquiring person but
also any persons acting in association with the acquiring person.

 

A
Nevada corporation may elect to opt out of the provisions of Sections 78.378 to 78.3793 of the NRS. We do not have a provision in our
Articles of Incorporation pursuant to which we have elected to opt out of Sections 78.378 to 78.3793; therefore, these sections apply
to us.

 

Removal
of Directors

 

Section
78.335 of the NRS provides that 2/3rds of the voting power of the issued and outstanding shares of the Company are required to remove
a Director from office. As such, it may be more difficult for stockholders to remove Directors due to the fact the NRS requires greater
than majority approval of the stockholders for such removal.Exhibit 10.1

 

LEASE TERMINATION AGREEMENT

 

THIS LEASE TERMINATION AGREEMENT
(this “Agreement”) is entered into as of this 22nd day of June, 2022 (“Effective Date”),
by and between BRE-BMR Pilgrim & Sidney LLC, a Delaware limited liability company, as successor-in-interest to UP 45/75 Sidney
Street, LLC (“Landlord”) and Voyager Therapeutics, Inc., a Delaware corporation (“Tenant”).

 

RECITALS

 

A.            WHEREAS,
Landlord and Tenant entered into that certain Lease dated as of April 1, 2014, as amended by that certain First Amendment to Lease
Agreement (the “First Amendment”) dated as of December 23, 2015, as further amended by that certain Second Amendment
to Lease Agreement (the “Second Amendment”) dated as of February 5, 2018, and as further amended by that certain
Third Amendment to Lease Agreement (the “Third Amendment”) dated as of June 1, 2018 (as the same may have been
amended, amended and restated, supplemented or otherwise modified from time to time, the “Lease”), whereby Tenant leases
certain premises consisting of 47,493 rentable square feet (the “Premises”) from Landlord in the building located at
75 Sidney Street in Cambridge, Massachusetts (the “Building”); and

 

B.            WHEREAS,
Landlord and Tenant desire to terminate the Lease in accordance with the provisions set forth herein; and

 

C.            WHEREAS,
Landlord acknowledges that Tenant has subleased 17,931 rentable square feet of the Premises on the fifth (5th) floor of the
Building (the “Subleased Premises”) to BioNTech US Inc. (“BioNTech”) pursuant to a Sublease Agreement
dated as of September 3, 2021 (the “BioNTech Sublease”), to which Landlord has consented pursuant to a Consent
to Sublease dated as of September 7, 2021; and

 

D.            WHEREAS,
Tenant currently occupies 29,562 rentable square feet on the fourth (4th) floor of the Building (“Tenant’s Remaining
Premises”); and

 

E.            WHEREAS,
simultaneously herewith, Landlord and BioNTech are entering into a direct lease of the Premises.

 

AGREEMENT

 

NOW, THEREFORE, Landlord and
Tenant, in consideration of the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, and intending to be legally bound, agree as follows:

 

1.             Surrender
Obligations. Tenant has previously delivered to Landlord a Cleaning, Decontamination and Sanitization Certification, issued April 28,
2022, together with a letter dated April 5, 2022 for Tenant’s Remaining Premises (collectively, the “Exit Survey”)
both prepared by Safety Partners, Inc., which Exit Survey has been accepted by Landlord. In addition, Tenant has (i) placed
laboratory equipment decontamination forms on all decommissioned fixtures and equipment remaining within the laboratory areas of the Tenant’s
Remaining Premises to assure safe occupancy by future users, (ii) provided written evidence of all appropriate governmental releases
obtained by Tenant in accordance with applicable laws, to the extent there are any, and (iii) conducted a site inspection of Tenant’s
Remaining Premises with Landlord. Landlord acknowledges and agrees that Tenant has no obligation to perform an Exit Survey or to carry
out any other surrender related obligations relating to the Subleased Premises. Notwithstanding anything in the Lease to the contrary,
Landlord acknowledges and agrees that Tenant’s movable trade fixtures, furnishings, goods and effects listed on Exhibit A
attached hereto (“Tenant Personal Property”) may remain in the Premises upon Lease Termination (as defined below).
Tenant represents that ownership of such Tenant Personal Property has been conveyed to BioNTech pursuant to a Bill of Sale as of Lease
Termination.

 

     

     

    

 

2.             Termination
Fee. There shall be no termination fee due in connection with this Lease Termination.

 

3.             Lease
Termination. Landlord acknowledges that Tenant has fully satisfied all of its surrender obligations set forth in Section 1
of this Agreement and in the Lease (“Surrender Obligations”). As of the Effective Date, Tenant hereby surrenders Tenant’s
Remaining Premises and the Subleased Premises to Landlord or at Landlord’s direction, to BioNTech. The Lease is hereby terminated
effective as of the Effective Date (“Lease Termination”). As of Lease Termination, the Lease shall be fully and finally
surrendered and terminated and shall no longer be of any force or effect, except for those provisions that, by their express terms, survive
the expiration or earlier termination of the Lease. Tenant represents that upon Lease Termination, the BioNTech Sublease shall also automatically
terminate, shall be fully and finally surrendered and shall no longer be of any force or effect, except for those provisions that, by
their express terms, survive the expiration or earlier termination of the BioNTech Sublease. Tenant’s Annual Fixed Rent, Tenant’s
Operating Expenses Allocable to the Premises and Tenant’s Tax Expenses Allocable to the Premises shall be apportioned between Landlord
and Tenant as of the Effective Date and paid, if applicable, to the party entitled to the same as set forth in the Lease.

 

4.             Reservation
of Rights. Notwithstanding any Lease Termination, neither Landlord nor Tenant waives, and each hereby reserves, any rights and/or
remedies that it may have under the Lease or at law or in equity arising from any default or breach by the other party under the Lease
existing as of the Lease Termination.

 

5.             Quitclaim.
To the extent, if any, that the Lease gives Tenant any right, title or interest in or to the Premises, Tenant does hereby remise, release
and quitclaim to Landlord such right, title or interest in or to the Premises as of the Lease Termination and shall execute and deliver
to Landlord any documentation reasonably requested by Landlord to effect or document such remise, release and quitclaim.

 

6.             Representation
of Parties. Each party represents that it has not made any assignment, sublease, transfer, conveyance or other disposition of the
Lease or any interest therein, other than the BioNTech Sublease, and has no knowledge of any agreement that would result in any mechanic’s
lien or other claim, demand, obligation, liability, action or cause of action arising from or with respect to the Lease or Tenant’s
Remaining Premises.

 

7.             Attorneys’
Fees. Except as otherwise expressly set forth in this Agreement, each party shall pay its own costs and expenses incurred in connection
with this Agreement and such party’s performance under this Agreement, provided, that if either party commences an action,
proceeding, demand, claim, action, cause of action or suit against the other party arising out of or in connection with this Agreement,
then the substantially prevailing party shall be reimbursed by the other party for all reasonable costs and expenses, including reasonable
attorneys’ fees and expenses, incurred by the substantially prevailing party in such action, proceeding, demand, claim, action,
cause of action or suit, and in any appeal in connection therewith (regardless of whether the applicable action, proceeding, demand, claim,
action, cause of action, suit or appeal is voluntarily withdrawn or dismissed).

 

     

     

    

 

8.             Integration.
The terms of this Agreement are intended by the parties as a final, complete and exclusive expression of their agreement with respect
to the terms that are included in this Agreement, and may not be contradicted or supplemented by evidence of any other prior or contemporaneous
agreement.

 

9.             Successors
and Assigns. Each of the covenants, conditions and agreements contained in this Agreement shall inure to the benefit of and shall
apply to and be binding upon the parties hereto and their respective administrators and permitted successors, assigns and sublessees.
Nothing in this section shall in any way alter the provisions of the Lease restricting assignment and subletting.

 

10.           Governing
Law. This Agreement shall be governed by and construed and enforced in accordance with the laws of the Commonwealth of Massachusetts,
without regard to Massachusetts’ conflict of law principles.

 

11.           Authority.
Each of the parties hereto guarantees, warrants and represents that the execution and consummation of this Agreement have been duly authorized
by all appropriate company action, and the individual or individuals signing this Agreement have the power, authority and legal capacity
to sign this Agreement on behalf of and to bind all entities, corporations, partnerships, limited liability companies, joint venturers
or other organizations and entities on whose behalf such individual or individuals have signed.

 

12.           Counterparts.
This Agreement may be executed in one or more counterparts, each of which, when taken together, shall constitute one and the same document.

 

13.           Amendment.
No provision of this Agreement may be modified, amended or supplemented except by an agreement in writing signed by Landlord and Tenant.

 

14.           Waiver
of Jury Trial. To the extent permitted by applicable laws, the parties waive trial by jury in any action, proceeding or counterclaim
brought by the other party hereto related to matters arising out of or in any way connected with this Agreement or Tenant’s use
or occupancy of the Premises or any claim of injury or damage related to this Agreement or the Premises.

 

15.           Facsimile
and PDF Signatures. A facsimile or portable document format (PDF) signature or electronic signature on this Agreement shall be equivalent
to, and have the same force and effect as, an original signature.

 

16.           Voluntary
Agreement. The parties have read this Agreement and the mutual releases contained in it, and have freely and voluntarily entered into
this Agreement.

 

17.           Defined
Terms. Capitalized terms not otherwise defined herein shall have the meanings given them in the Lease.

 

     

     

    

 

IN WITNESS WHEREOF, the parties
have caused this Agreement to be executed as a sealed Massachusetts instrument as of the day hereinabove first written.

 

LANDLORD:

 

BRE-BMR
Pilgrim & Sidney LLC,

a Delaware limited liability company

 

 

	By:	/s/ Colleen O'Connor	 
	Name: 	Colleen O'Connor	 
	Its: 	SVP, Leasing, East Coast & UK Mkts	 

 

 

TENANT:

 

Voyager Therapeutics, Inc.,

a Delaware corporation

 

 

	By:	 /s/ Robin Swartz	 
	Name: 	Robin Swartz	 
	Its: 	COO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]